Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06747845 |
| Title | Maintenance Niraparib Plus Ipilimumab in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy (ParpVax2) |
| Acronym | ParpVax2 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Abramson Cancer Center at Penn Medicine |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | United States | Details |